Inventor · disambiguated record
Robert J. Cherney
Also filed as: CHERNEY ROBERT · CHERNEY ROBERT J · CHERNEY ROBERT JOSEPH
40 granted patents·4 pending applications·346 citations·filing 1993–2024
97Inventor score
Files withBRISTOL MYERS SQUIBB CO28BRISTOL MYERS SQUIBB PHARMA CO5DU PONT MERCK PHARMA5CHERNEY ROBERT J3BRISTOL MYERS SQUIBB PHARMACEU1
Top patents by PatentIndex Score
44 records- 0193US7183270B2Cyclic derivatives as modulators of chemokine receptor activityBRISTOL MYERS SQUIBB CO·Filed 2004·Granted Feb 27, 2007·52 cites·19 claims
- 0292US6706712B2Cyclic derivatives as modulators of chemokine receptor activityBRISTOL MYERS SQUIBB PHARMA CO·Filed 2001·Granted Mar 16, 2004·57 cites·29 claims
- 0391US7087604B2Cyclic derivatives as modulators of chemokine receptor activityBRISTOL MYERS SQUIBB CO·Filed 2003·Granted Aug 8, 2006·23 cites·19 claims
- 0490US9815859B2Tricyclic sulfones as RORγ modulatorsBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Nov 14, 2017·11 cites·15 claims
- 0589US7163937B2Cyclic derivatives as modulators of chemokine receptor activityBRISTOL MYERS SQUIBB CO·Filed 2004·Granted Jan 16, 2007·29 cites·19 claims
- 0688US8383812B2N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processesBRISTOL MYERS SQUIBB CO·Filed 2010·Granted Feb 26, 2013·9 cites·15 claims
- 0788US6927216B2Cyclic sulfonyl compounds as inhibitors of metalloproteasesBRISTOL MYERS SQUIBB PHARMA CO·Filed 2001·Granted Aug 9, 2005·22 cites·24 claims
- 0886US10273259B2Tricyclic sulfones as RORγ modulatorsBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Apr 30, 2019·4 cites·1 claims
- 0985US11524959B1Indole and azaindole inhibitors of pad enzymesBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Dec 13, 2022·3 cites·18 claims
- 1084US7482335B2Cyclic derivatives as modulators of chemokine receptor activityBRISTOL MYERS SQUIBB CO·Filed 2006·Granted Jan 27, 2009·6 cites·21 claims
- 1184US7338947B2Cyclic derivatives as modulators of chemokine receptor activityBRISTOL MYERS SQUIBB CO·Filed 2006·Granted Mar 4, 2008·6 cites·21 claims
- 1283US8629282B2Heterocyclic compounds as S1P1 agonists for the treatment of autoimmune and vascular diseasesCHERNEY ROBERT J·Filed 2011·Granted Jan 14, 2014·9 cites·7 claims
- 1383US6974836B2Diamines as modulators of chemokine receptor activityBRISTOL MYERS SQUIBB PHARMA CO·Filed 2001·Granted Dec 13, 2005·19 cites·26 claims
- 1482US7378409B2Substituted cycloalkylamine derivatives as modulators of chemokine receptor activityBRISTOL MYERS SQUIBB CO·Filed 2004·Granted May 27, 2008·20 cites·9 claims
- 1581US7671062B2Modulators of chemokine receptor activity, crystalline forms and processBRISTOL MYERS SQUIBB CO·Filed 2007·Granted Mar 2, 2010·4 cites·9 claims
- 1678US8642622B2Piperidinyl compound as a modulator of chemokine receptor activityCHERNEY ROBERT J·Filed 2011·Granted Feb 4, 2014·4 cites·8 claims
- 1777US8618101B2N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processesBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Dec 31, 2013·2 cites·2 claims
- 1877US7291615B2Cyclic derivatives as modulators of chemokine receptor activityBRISTOL MYERS SQUIBB CO·Filed 2004·Granted Nov 6, 2007·7 cites·21 claims
- 1975US10023576B2Heteroaryl substituted pyrrolotriazine amine compounds as PI3K inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Jul 17, 2018·2 cites·10 claims
- 2070US9216972B2Tricyclic heterocyclic compoundsDHAR T G MURALI·Filed 2010·Granted Dec 22, 2015·2 cites·16 claims
- 2170US5376664AUnsymmetrical mono-3-nitro bis-naphthalimides as anticancer agentsDU PONT MERCK PHARMA·Filed 1993·Granted Dec 27, 1994·11 cites·8 claims
- 2268US10711020B2Tricyclic sulfones as RORγ modulatorsBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Jul 14, 2020·0 cites·1 claims
- 2368US7045521B2Cyclic derivatives as modulators of chemokine receptor activityBRISTOL MYERS SQUIBB PHARMA CO·Filed 2003·Granted May 16, 2006·3 cites·15 claims
- 2467US2025145590A1Ubiquitin specific processing protease 1 (usp1) compoundsBRISTOL MYERS SQUIBB CO·Filed 2024·Application pending·0 cites
- 2563US8906920B2N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processesBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Dec 9, 2014·0 cites·1 claims
- 2663US7829571B2Cyclic derivatives as modulators of chemokine receptor activityBRISTOL MYERS SQUIBB CO·Filed 2009·Granted Nov 9, 2010·0 cites·18 claims
- 2762US7696205B2Cyclic derivatives as modulators of chemokine receptor activityBRISTOL MYERS SQUIBB CO·Filed 2007·Granted Apr 13, 2010·0 cites·16 claims
- 2861US2008114052A1Cyclic derivatives as modulators of chemokine receptor activityBRISTOL MYERS SQUIBB CO·Filed 2008·Application pending·0 cites
- 2958US2024217982A1Kras inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2022·Application pending·0 cites
- 3058US2024317769A1Kras g12d inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2022·Application pending·0 cites
- 3157US5416089APolycyclic and heterocyclic chromophores for bis-imide tumoricidalsDU PONT MERCK PHARMA·Filed 1993·Granted May 16, 1995·12 cites·15 claims
- 3255US7572813B2Cyclic derivatives as modulators of chemokine receptor activityBRISTOL MYERS SQUIBB CO·Filed 2005·Granted Aug 11, 2009·0 cites·14 claims
- 3353US7776884B2Cyclic derivatives as modulators of chemokine receptors activityBRISTOL MYERS SQUIBB CO·Filed 2006·Granted Aug 17, 2010·0 cites·20 claims
- 3450US6281352B1Macrocyclic compounds as metalloprotease inhibitorsDU PONT PHARM CO·Filed 1997·Granted Aug 28, 2001·10 cites·50 claims
- 3549US7687508B2Cyclic derivatives as modulators of chemokine receptor activityBRISTOL MYERS SQUIBB CO·Filed 2007·Granted Mar 30, 2010·0 cites·11 claims
- 3647US5691381AHydroxamic and carbocyclic acids as metalloprotease inhibitorsDU PONT MERCK PHARMA·Filed 1996·Granted Nov 25, 1997·7 cites·4 claims
- 3747US5585382APolycyclic and heterocyclic chromophores for bis-imide tumoricidalsDU PONT MERCK PHARMA·Filed 1995·Granted Dec 17, 1996·7 cites·14 claims
- 3846US12473304B2Heterocyclic PAD4 inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2021·Granted Nov 18, 2025·0 cites·29 claims
- 3946US7449493B2Diamines as modulators of chemokine receptor activityBRISTOL MYERS SQUIBB PHARMACEU·Filed 2005·Granted Nov 11, 2008·0 cites·19 claims
- 4045US5359070AUnsymmetrical bis-imides as anticancer agentsDU PONT MERCK PHARMA·Filed 1993·Granted Oct 25, 1994·2 cites·4 claims
- 4141US10934286B2Heterocyclic sulfones as ROR gamma modulatorsBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Mar 2, 2021·0 cites·20 claims
- 4239US6455522B1Cyclic sulfonamide derivatives as metalloproteinase inhibitorsBRISTOL MYERS SQUIBB PHARMA CO·Filed 1999·Granted Sep 24, 2002·3 cites·36 claims
- 4335US10214537B2Bicyclic heteroaryl amine compoundsBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Feb 26, 2019·0 cites·9 claims
- 4435US8835470B2Mandelamide heterocyclic compoundsCHERNEY ROBERT J·Filed 2011·Granted Sep 16, 2014·0 cites·12 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →